roche holding ag - RHHVF
RHHVF
Close Chg Chg %
422.65 18.80 4.45%
Closed Market
441.45
+18.80 (4.45%)
Volume: 682.00
Last Updated:
Jan 15, 2026, 3:55 PM EDT
Company Overview: roche holding ag - RHHVF
RHHVF Key Data
| Open $425.82 | Day Range 425.82 - 442.36 |
| 52 Week Range 277.00 - 432.00 | Market Cap N/A |
| Shares Outstanding NaN | Public Float 689.63M |
| Beta N/A | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS N/A |
| Yield N/A | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 5.52K |
RHHVF Performance
| 1 Week | 4.73% | ||
| 1 Month | 6.09% | ||
| 3 Months | 22.31% | ||
| 1 Year | 52.91% | ||
| 5 Years | 25.59% |
RHHVF Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
23
Full Ratings ➔
An error occurred while fetching the data.
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Roche Holding Ag - RHHVF
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 68.69B | 66.26B | 65.34B | 68.69B | |
Sales Growth
| +10.55% | -3.54% | -1.39% | +5.13% | |
Cost of Goods Sold (COGS) incl D&A
| 21.55B | 19.72B | 17.60B | 18.20B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 4.86B | 4.00B | 3.87B | 3.89B | |
Depreciation
| 3.16B | 3.02B | 3.07B | 3.05B | |
Amortization of Intangibles
| 1.70B | 982.13M | 796.75M | 842.54M | |
COGS Growth
| +23.69% | -8.48% | -10.76% | +3.38% | |
Gross Income
| 47.14B | 46.54B | 47.74B | 50.49B | |
Gross Income Growth
| +5.42% | -1.28% | +2.58% | +5.78% | |
Gross Profit Margin
| +68.63% | +70.23% | +73.06% | +73.51% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 27.98B | 27.30B | 29.31B | 29.52B | |
Research & Development
| 14.99B | 14.71B | 14.72B | 14.26B | |
Other SG&A
| 12.98B | 12.59B | 14.59B | 15.26B | |
SGA Growth
| +9.52% | -2.40% | +7.35% | +0.70% | |
Other Operating Expense
| 260.32M | 201.03M | 233.68M | 275.93M | |
Unusual Expense
| 3.03B | 4.59B | 3.55B | 7.98B | |
EBIT after Unusual Expense
| 15.88B | 14.44B | 14.65B | 12.73B | |
Non Operating Income/Expense
| 3.53B | 3.33B | 1.98B | 2.13B | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 372.98M | 636.61M | 921.38M | 1.42B | |
Interest Expense Growth
| -20.07% | +70.68% | +44.73% | +53.80% | |
Gross Interest Expense
| 372.98M | 636.61M | 921.38M | 1.42B | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 19.03B | 17.14B | 15.70B | 13.44B | |
Pretax Income Growth
| -0.57% | -9.95% | -8.38% | -14.39% | |
Pretax Margin
| +27.71% | +25.87% | +24.03% | +19.57% | |
Income Tax
| 2.69B | 2.93B | 1.92B | 2.96B | |
Income Tax - Current - Domestic
| 2.86B | 4.66B | 3.15B | 4.91B | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (170.63M) | (1.74B) | (1.24B) | (1.95B) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 16.34B | 14.17B | 13.75B | 10.43B | |
Minority Interest Expense
| 1.10B | 1.16B | 956.99M | 1.03B | |
Net Income
| 15.24B | 13.01B | 12.79B | 9.40B | |
Net Income Growth
| +0.04% | -14.64% | -1.62% | -26.54% | |
Net Margin Growth
| +22.18% | +19.63% | +19.58% | +13.68% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 15.24B | 13.01B | 12.79B | 9.40B | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 15.24B | 13.01B | 12.79B | 9.40B | |
EPS (Basic)
| 17.925 | 16.2567 | 16.0134 | 11.7924 | |
EPS (Basic) Growth
| +0.63% | -9.31% | -1.50% | -26.36% | |
Basic Shares Outstanding
| 850.00M | 800.00M | 799.00M | 797.00M | |
EPS (Diluted)
| 17.7153 | 16.2567 | 15.9138 | 11.7189 | |
EPS (Diluted) Growth
| +0.62% | -8.23% | -2.11% | -26.36% | |
Diluted Shares Outstanding
| 860.00M | 800.00M | 804.00M | 802.00M | |
EBITDA
| 23.77B | 23.03B | 22.06B | 24.60B | |
EBITDA Growth
| +0.07% | -3.09% | -4.23% | +11.51% | |
EBITDA Margin
| +34.60% | +34.76% | +33.76% | +35.81% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 419.845 | |
| Number of Ratings | 23 | Current Quarters Estimate | N/A | |
| FY Report Date | N/A | Current Year's Estimate | 25.718 | |
| Last Quarter’s Earnings | 10.841 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 24.713 | Next Fiscal Year Estimate | 27.24 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | N/A | N/A | 19 | 19 |
| Mean Estimate | N/A | N/A | 25.72 | 27.24 |
| High Estimates | N/A | N/A | 27.59 | 30.15 |
| Low Estimate | N/A | N/A | 24.61 | 25.88 |
| Coefficient of Variance | N/A | N/A | 3.07 | 4.29 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 9 |
| OVERWEIGHT | 4 | 3 | 2 |
| HOLD | 7 | 8 | 7 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 3 | 3 | 5 |
| MEAN | Overweight | Overweight | Hold |
SEC Filings for Roche Holding Ag - RHHVF
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
An error occurred while fetching the data.
Roche Holding Ag in the News
Merck COVID-19 pill success slams Moderna shares, shakes up health care sector
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.
Inside the race for a COVID-19 treatment pill
Pfizer and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG are racing to produce the first antiviral pill that people could take at early signs of the illness. Their shared goal: filling a key treatment hole by helping people recently-infected with coronavirus to avoid becoming seriously ill and needing hospitalization.